Yin Hong-fang, Li Ting
Department of Pathology, Peking University First Hospital, Beijing 100034, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2007 Apr 18;39(2):158-62.
Primary nodal and extranodal diffuse large B-cell lymphoma (DLBCL) were investigated for the heterogeneity of histopathology and immunophenotype, and their relation to clinical stage, comparatively. Whether E2F1 can be used as a germinal center B cell (GCB) DLBCL marker was also discussed.
Classification of histopathology and immunophenotype of 98 cases were studied by immunohistochemistry in tissue microarray.
Histopathologic morphology presented as: centroblastic (CB,88.8%, 87/98), immunoblastic (IB,5.1%, 5/98), anaplastic (ALCL,3.1%, 3/98), and T cell rich B cell lymphoma (TCRBCL,3.1%, 3/98). Of which, 31 cases were GCB DLBCL, 10 (20.8%, 10/48) nodal, and 21 extranodal (42%, 21/50, P=0.024). The rates of Stages I/II in nodal and extranodal area were 48.5% and 70%, respectively (P=0.015). The rate of Stage I/ II in GCB DLBCL (74.2%) were higher than in non-GCB DLBCL (50.7%, P=0.029). The CD10 positive rates were 36.8% and 17.1% in Stages I/II and III/IV, respectively, and had significant differences (P=0.033). The CD10 positive rates were 18.8% and 38% in nodal and extranodal area, respectively (P=0.035). The positive rates of E2F1 were 38.8% and 16.5% in GCB and non-GCB DLBCL, respectively, and had significant differences (P=0.016). The positive rate of E2F1 had positive relation with the expression of CD10 and Bcl-6 (P<0.05).
CB is the most type in 98 cases of DLBCL. The rate of GCB DLBCL was significant higher in extranodal than in nodal areas CD 10 can be used as a prognostic marker. The prognosis of GCB DLBCL is better than that of non-GCB DLBCL. The positive expression of E2F1 can be used as a marker of GCB DLBCL.
比较原发性淋巴结及结外弥漫性大B细胞淋巴瘤（DLBCL）组织病理学和免疫表型的异质性及其与临床分期的关系。探讨E2F1是否可作为生发中心B细胞（GCB）DLBCL的标志物。
采用免疫组织化学方法对组织芯片中98例病例的组织病理学和免疫表型进行分类研究。
组织病理学形态表现为：中心母细胞型（CB，88.8%，87/98）、免疫母细胞型（IB，5.1%，5/98）、间变性（ALCL，3.1%，3/98）和富于T细胞的B细胞淋巴瘤（TCRBCL，3.1%，3/98）。其中，31例为GCB DLBCL，10例（20.8%，10/48）为淋巴结型，21例（42%，21/50）为结外型（P = 0.024）。淋巴结区和结外区Ⅰ/Ⅱ期的比例分别为48.5%和70%（P = 0.015）。GCB DLBCL中Ⅰ/Ⅱ期的比例（74.2%）高于非GCB DLBCL（50.7%，P = 0.029）。CD10阳性率在Ⅰ/Ⅱ期和Ⅲ/Ⅳ期分别为36.8%和17.1%，差异有统计学意义（P = 0.033）。CD10阳性率在淋巴结区和结外区分别为18.8%和38%（P = 0.035）。E2F1阳性率在GCB和非GCB DLBCL中分别为38.8%和16.5%，差异有统计学意义（P = 0.016）。E2F1阳性率与CD10和Bcl-6的表达呈正相关（P < 0.05）。
98例DLBCL中CB型最多见。结外GCB DLBCL的比例显著高于淋巴结区。CD10可作为预后标志物。GCB DLBCL的预后优于非GCB DLBCL。E2F1的阳性表达可作为GCB DLBCL的标志物。
